{"nctId":"NCT00030901","briefTitle":"S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate","startDateStruct":{"date":"2000-02"},"conditions":["Precancerous/Nonmalignant Condition","Prostate Cancer"],"count":619,"armGroups":[{"label":"L-selenomethionine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: L-selenomethionine"]},{"label":"L-selenomethionine placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: L-selenomethionine placebo"]}],"interventions":[{"name":"L-selenomethionine","otherNames":["Selenium"]},{"name":"L-selenomethionine placebo","otherNames":["placebo"]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Diagnosis of high-grade prostatic intraepithelial neoplasia with no evidence of cancer\n\n  * Documented by a digital rectal exam and biopsy of the prostate with transrectal ultrasound guidance (required if fewer than 6 cores obtained in biopsy) meeting one of the following conditions:\n\n    * Biopsy yielded fewer than 10 cores within the past 24 months OR yielded more than 10 cores 6-24 months before study\n    * Biopsy yielded 10 or more cores within the past 6 months\n* PSA ≤ 10 ng/mL (≤ 5 ng/mL for patients who have received finasteride or other androgen suppressor within the past 2 months)\n* American Urological Association symptom score of less than 20\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 40 and over\n\nPerformance status:\n\n* SWOG 0-1\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* Not specified\n\nHepatic:\n\n* Not specified\n\nRenal:\n\n* Not specified\n\nOther:\n\n* No malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or adequately treated stage I or II cancer that is in complete remission\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* Not specified\n\nEndocrine therapy\n\n* See Disease Characteristics\n* No concurrent finasteride or any other androgen suppressor\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Not specified\n\nOther\n\n* At least 30 days since prior daily dietary supplements containing 50 micrograms or more of selenium\n* No concurrent daily dietary supplements containing more than 50 micrograms of selenium","healthyVolunteers":false,"sex":"MALE","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Presence of Carcinoma of the Prostate as Measured by Biopsy","description":"The primary endpoint is biopsy-proven presence/absence of carcinoma of the prostate within 3 years after randomization to treatment. An end-of-study biopsy at 3 years after randomization will be used to determine presence/absence of prostate carcinoma in those patients not previously diagnosed with prostate carcinoma on study. Biopsies performed within ± 90 days of the 3-year anniversary will be considered end-of-study biopsies. Pathologically confirmed presence of prostate carcinoma may be determined at any time during the 3 years and 90 days after randomization, but absence can only be determined by the end-of-study biopsy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug","description":"Adverse Events (AEs) are reported by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 2.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":203},"commonTop":["Fatigue/malaise/lethargy","Urinary frequency/urgency","Nail changes","GI-other","Rash/desquamation"]}}}